At the one - year mark, the ADRC treated patients with at least one class improvement in heart failure class (57 percent) and
angina class (67 percent) tended to be higher relative to the placebo group (15 percent and 27 percent, respectively).
The patients were also CCS
angina class II - IV and / or NYHA class II - III, had ongoing ischemia and multi-vessel cardiovascular disease, but were not candidates for revascularization.
Not exact matches
The best case scenario for an individual diagnosed with stable
angina may be a standard health
class with a select few companies.